Back to top

biotechnology: Archive

Zacks Equity Research

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

ALNYPositive Net Change NVSPositive Net Change ALLOPositive Net Change BBIOPositive Net Change

Zacks Equity Research

Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?

EXEL's shares move north 25% in a month on the back of strong third-quarter results and raised outlook. We are optimistic about the stock as we believe there is room for growth.

MRKPositive Net Change EXELNegative Net Change SPRONegative Net Change CSTLPositive Net Change

Zacks Equity Research

Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?

Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.

REGNPositive Net Change

Zacks Equity Research

Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.

NVSPositive Net Change PFEPositive Net Change GILDNegative Net Change

Ahan Chakraborty

Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.

NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change

Zacks Equity Research

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.

BMYPositive Net Change PFEPositive Net Change REPLPositive Net Change ALLOPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

SAGE and INCY suffer setbacks due to the failure of HD and CSU studies, respectively.

INCYPositive Net Change JAZZPositive Net Change PYXSPositive Net Change

Zacks Equity Research

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.

PFEPositive Net Change AMGNPositive Net Change ALLOPositive Net Change SLNPositive Net Change